Eli Lilly (LLY) and Incyte (INCY) have made significant headway with the drug Baricitinib as recent studies show positive results in the treatment of rheumatoid arthritis.

The trials so far have yielded statistically significant results that support the efficacy of the drug. Essentially, the drug has achieved its primary endpoint in studies so far, which is the best that Eli Lilly could ask for at this point in the testing game. Subjects were randomly assigned in this double blind study and the validity of the methods used is not in question at all. Study groups that took 4mg doses of Baricitinib combined with the group that took 8mg doses of Baricitinib achieved a 76% response as compared to the placebo group which achieved only a 41% response.

It must be noted that during the trials the “most common treatment-emergent adverse event class was infections”. This is something worth looking out for. In addition, the final stage of testing still needs to be conducted.

These are very positive results and good news for the company as a whole. However, there is still a long way to go in terms of the drug Baricitinib and it is difficult at this point to analyze whether or not success is around the corner. However, in terms of Eli Lilly stock, this news is most likely a game changer and investors should keep a close eye on the long-term results.

Pharmaceutical companies have realized that in order to make a mark on the market they have to start addressing serous condition in earnest.To continue reading, click here.